CEO Stephen Isaacs describes Aduro Biotech Inc.'s recently signed immuno-oncology collaboration with Stanford University as an effort to join wheels to a car, "so hopefully we can go on a very nice journey together."
The agreement, announced Jan. 17, will combine Aduro's personalized live, attenuated double-deleted Listeria (LADD) immunotherapy platform with an algorithm developed by Stanford associate professor of medicine Hanlee Ji to identify...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?